Protara Therapeutics
TARA
76 hedge funds and large institutions have $90.1M invested in Protara Therapeutics in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 8 closing their positions.
213% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 8
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
29% more funds holding
Funds holding: 59 → 76 (+17)
2% more call options, than puts
Call options by funds: $215K | Put options by funds: $210K
1.2% less ownership
Funds ownership: 78.22% → 77.02% (-1.2%)
27% less capital invested
Capital invested by funds: $124M → $90.1M (-$33.7M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.22M |
| 2 |
CCM
Catalio Capital Management
New York
|
+$1.85M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.72M |
| 4 |
ACA
Acorn Capital Advisors
New York
|
+$1.63M |
| 5 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$8.14M |
| 2 |
SCM
Sio Capital Management
New York
|
-$6.45M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.02M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.16M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$370K |
TARA Hedge Fund Activity: Q2 2025 in Review
76 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2025, worth a combined $90.1M — down 27% from $124M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TARA positions and 8 closed out — a net gain of 17 holders — while 27 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $5.22M. The largest seller was RA Capital Management, cutting an estimated $8.14M.
- 76 institutional investors held Protara Therapeutics (TARA) as of Q2 2025, up from 59 in Q1 2025.
- Funds reported $90.1M of Protara Therapeutics stock for Q2 2025, down 27% quarter-over-quarter.
- 25 funds opened new Protara Therapeutics positions in Q2 2025 and 8 closed out, a net change of +17 holders.
- The largest Protara Therapeutics buyer in Q2 2025 was BlackRock, an estimated $5.22M added.
- The largest Protara Therapeutics seller in Q2 2025 was RA Capital Management, an estimated $8.14M sold.
Based on aggregated 13F filings for Q2 2025.